Karyopharm Therapeutics Inc (KPTI) Shares Bought by United Services Automobile Association

United Services Automobile Association grew its position in Karyopharm Therapeutics Inc (NASDAQ:KPTI) by 31.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 113,349 shares of the company’s stock after acquiring an additional 26,973 shares during the quarter. United Services Automobile Association owned approximately 0.19% of Karyopharm Therapeutics worth $1,926,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Northern Trust Corp increased its holdings in shares of Karyopharm Therapeutics by 51.5% in the 2nd quarter. Northern Trust Corp now owns 601,974 shares of the company’s stock valued at $10,226,000 after acquiring an additional 204,680 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Karyopharm Therapeutics by 28.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 214,018 shares of the company’s stock valued at $3,636,000 after acquiring an additional 46,911 shares during the last quarter. California Public Employees Retirement System bought a new stake in shares of Karyopharm Therapeutics in the 2nd quarter valued at approximately $339,000. MetLife Investment Advisors LLC increased its holdings in shares of Karyopharm Therapeutics by 51.1% in the 2nd quarter. MetLife Investment Advisors LLC now owns 23,047 shares of the company’s stock valued at $392,000 after acquiring an additional 7,793 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY increased its holdings in shares of Karyopharm Therapeutics by 38.9% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 16,275 shares of the company’s stock valued at $277,000 after acquiring an additional 4,556 shares during the last quarter. Institutional investors and hedge funds own 71.57% of the company’s stock.

NASDAQ:KPTI opened at $12.27 on Friday. Karyopharm Therapeutics Inc has a 12-month low of $9.00 and a 12-month high of $21.71.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Tuesday, August 7th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $0.21. The company had revenue of $19.89 million for the quarter, compared to analyst estimates of $5.97 million. On average, sell-side analysts anticipate that Karyopharm Therapeutics Inc will post -3.18 earnings per share for the current fiscal year.

In other Karyopharm Therapeutics news, major shareholder Ltd Chione sold 20,000 shares of the business’s stock in a transaction on Monday, July 23rd. The stock was sold at an average price of $18.66, for a total transaction of $373,200.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Sharon Shacham sold 12,500 shares of the business’s stock in a transaction on Monday, October 8th. The stock was sold at an average price of $15.75, for a total value of $196,875.00. Following the transaction, the insider now owns 715,274 shares of the company’s stock, valued at approximately $11,265,565.50. The disclosure for this sale can be found here. Insiders have sold a total of 867,305 shares of company stock valued at $17,302,128 in the last 90 days. Insiders own 13.26% of the company’s stock.

KPTI has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, August 29th. ValuEngine downgraded Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 11th. Zacks Investment Research upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $21.00 price objective for the company in a research report on Wednesday, July 25th. Robert W. Baird restated a “buy” rating and set a $25.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, August 8th. Finally, BidaskClub lowered Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 25th. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $22.90.

Karyopharm Therapeutics Profile

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.

Read More: Growth Stocks, What They Are, What They Are Not

Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply